Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 7.66 Million AUD | -25.93% |
| 2023 | 10.34 Million AUD | 27.83% |
| 2022 | 6.79 Million AUD | 5536.33% |
| 2021 | 120.55 Thousand AUD | 1122.16% |
| 2020 | 9864.00 AUD | -61.23% |
| 2019 | 25.44 Thousand AUD | -86.56% |
| 2018 | 189.25 Thousand AUD | -63.5% |
| 2017 | 518.5 Thousand AUD | -37.12% |
| 2016 | 824.58 Thousand AUD | -59.01% |
| 2015 | 2.01 Million AUD | -55.92% |
| 2014 | 4.56 Million AUD | 35.15% |
| 2013 | 3.37 Million AUD | -70.2% |
| 2012 | 11.33 Million AUD | -38.0% |
| 2011 | 18.27 Million AUD | 87.31% |
| 2010 | 9.75 Million AUD | 46.3% |
| 2009 | 6.66 Million AUD | -57.62% |
| 2008 | 15.73 Million AUD | 14.37% |
| 2007 | 13.75 Million AUD | 39.0% |
| 2006 | 9.89 Million AUD | 4.53% |
| 2005 | 9.46 Million AUD | 150.29% |
| 2004 | 3.78 Million AUD | -59.16% |
| 2003 | 9.26 Million AUD | -29.32% |
| 2002 | 13.1 Million AUD | 132.68% |
| 2001 | 5.63 Million AUD | 40.17% |
| 2000 | 4.01 Million AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.43 Million AUD | -46.24% |
| 2024 FY | 7.66 Million AUD | -11.76% |
| 2024 Q2 | 3.95 Million AUD | 0.0% |
| 2024 Q3 | 2.39 Million AUD | -39.38% |
| 2024 Q4 | 2.39 Million AUD | 0.0% |
| 2023 FY | 8.68 Million AUD | 27.83% |
| 2023 Q1 | 2.48 Million AUD | -47.53% |
| 2023 Q3 | 2.68 Million AUD | -35.36% |
| 2023 Q4 | 4.53 Million AUD | 68.79% |
| 2023 Q2 | 4.15 Million AUD | 66.9% |
| 2022 Q3 | 2.88 Million AUD | 40.5% |
| 2022 Q2 | 2.05 Million AUD | 18.73% |
| 2022 Q4 | 4.74 Million AUD | 64.62% |
| 2022 FY | 6.79 Million AUD | 5536.33% |
| 2022 Q1 | 1.72 Million AUD | 1559.16% |
| 2021 Q2 | 16.43 Thousand AUD | 100.0% |
| 2021 Q1 | 8218.00 AUD | -11.42% |
| 2021 FY | 120.55 Thousand AUD | 1122.16% |
| 2021 Q4 | 104.11 Thousand USD | -84.2% |
| 2021 Q3 | 659.14 Thousand AUD | 3910.4% |
| 2020 Q4 | 9278.00 AUD | 100.0% |
| 2020 FY | 9864.00 AUD | -61.23% |
| 2020 Q2 | 586.00 AUD | 100.0% |
| 2020 Q3 | 4639.00 AUD | 691.64% |
| 2020 Q1 | 293.00 AUD | -95.84% |
| 2019 Q1 | 9201.00 AUD | -79.88% |
| 2019 FY | 25.44 Thousand AUD | -86.56% |
| 2019 Q2 | 9201.00 AUD | 0.0% |
| 2019 Q3 | 3521.00 AUD | -61.73% |
| 2019 Q4 | 7042.00 USD | 100.0% |
| 2018 Q4 | 45.73 Thousand AUD | 0.0% |
| 2018 FY | 189.25 Thousand AUD | -63.5% |
| 2018 Q2 | 48.89 Thousand AUD | 0.0% |
| 2018 Q1 | 48.89 Thousand AUD | -34.53% |
| 2018 Q3 | 45.73 Thousand AUD | -6.47% |
| 2017 Q4 | 74.68 Thousand AUD | 0.0% |
| 2017 Q3 | 74.68 Thousand AUD | -59.54% |
| 2017 Q2 | 184.56 Thousand AUD | 0.0% |
| 2017 Q1 | 184.56 Thousand AUD | -14.46% |
| 2017 FY | 518.5 Thousand AUD | -37.12% |
| 2016 Q4 | 215.76 Thousand AUD | 0.0% |
| 2016 Q2 | 196.52 Thousand AUD | 0.0% |
| 2016 Q1 | 196.52 Thousand AUD | -48.27% |
| 2016 Q3 | 215.76 Thousand AUD | 9.79% |
| 2016 FY | 824.58 Thousand AUD | -59.01% |
| 2015 FY | 2.01 Million AUD | -55.92% |
| 2015 Q4 | 379.87 Thousand AUD | 0.0% |
| 2015 Q3 | 379.87 Thousand AUD | -39.33% |
| 2015 Q2 | 626.08 Thousand AUD | 0.0% |
| 2015 Q1 | 626.08 Thousand AUD | -50.84% |
| 2014 Q4 | 1.27 Million AUD | 0.0% |
| 2014 FY | 4.56 Million AUD | 35.15% |
| 2014 Q2 | 1 Million AUD | -0.0% |
| 2014 Q1 | 1 Million AUD | 24.58% |
| 2014 Q3 | 1.27 Million AUD | 26.26% |
| 2013 Q1 | 878.93 Thousand AUD | 0.0% |
| 2013 FY | 3.37 Million AUD | -70.2% |
| 2013 Q3 | 809.65 Thousand AUD | -7.88% |
| 2013 Q2 | 878.93 Thousand AUD | -0.0% |
| 2013 Q4 | 809.65 Thousand AUD | 0.0% |
| 2012 FY | 11.33 Million AUD | -38.0% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | 18.27 Million AUD | 87.31% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 9.75 Million AUD | 46.3% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 6.66 Million AUD | -57.62% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | 15.73 Million AUD | 14.37% |
| 2008 Q1 | 4.42 Million AUD | -30.1% |
| 2008 Q2 | 4.54 Million AUD | 2.72% |
| 2008 Q4 | 3.33 Million AUD | -49.76% |
| 2008 Q3 | 6.63 Million AUD | 46.04% |
| 2007 Q3 | 4.24 Million AUD | 115.85% |
| 2007 Q4 | 6.32 Million AUD | 49.14% |
| 2007 FY | 13.75 Million AUD | 39.0% |
| 2007 Q2 | 1.96 Million AUD | -27.47% |
| 2007 Q1 | 2.7 Million AUD | 23.61% |
| 2006 Q3 | 2.56 Million AUD | -23.58% |
| 2006 Q4 | 2.19 Million AUD | -14.72% |
| 2006 Q1 | 3.37 Million AUD | 426.69% |
| 2006 FY | 9.89 Million AUD | 4.53% |
| 2006 Q2 | 3.36 Million AUD | -0.43% |
| 2005 FY | 9.46 Million AUD | 150.29% |
| 2005 Q4 | -1.03 Million AUD | -129.1% |
| 2005 Q1 | 3.76 Million AUD | 0.0% |
| 2005 Q2 | 3.51 Million AUD | -6.74% |
| 2005 Q3 | 3.55 Million AUD | 1.17% |
| 2004 FY | 3.78 Million AUD | -59.16% |
| 2003 FY | 9.26 Million AUD | -29.32% |
| 2002 FY | 13.1 Million AUD | 132.68% |
| 2001 FY | 5.63 Million AUD | 40.17% |
| 2000 FY | 4.01 Million AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 75.472% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | 42.661% |
| Aspira Women's Health Inc. | 9.15 Million USD | 16.268% |
| Biodesix, Inc. | 49.08 Million USD | 84.385% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | 21.554% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -202.657% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -202.657% |
| Bionano Genomics, Inc. | 36.11 Million USD | 78.777% |
| CareDx, Inc | 280.32 Million USD | 97.266% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | 96.513% |
| DarioHealth Corp. | 20.35 Million USD | 62.339% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.693% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 97.35% |
| Guardant Health, Inc. | 563.94 Million USD | 98.641% |
| ICON Public Limited Company | 8.12 Billion USD | 99.906% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.791% |
| Illumina, Inc. | 4.5 Billion USD | 99.83% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -146.315% |
| iSpecimen Inc. | 9.92 Million USD | 22.798% |
| Standard BioTools Inc. | 106.34 Million USD | 92.792% |
| MDxHealth SA | 70.19 Million USD | 89.08% |
| 23andMe Holding Co. | 219.63 Million USD | 96.51% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.594% |
| Myriad Genetics, Inc. | 678.4 Million USD | 98.87% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -755.942% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | 98.704% |
| Neogen Corporation | 924.22 Million USD | 99.171% |
| Inotiv, Inc. | 572.42 Million USD | 98.661% |
| Natera, Inc. | 1.08 Billion USD | 99.292% |
| OpGen, Inc. | 3.41 Million USD | -124.227% |
| OPKO Health, Inc. | 863.49 Million USD | 99.112% |
| Psychemedics Corporation | 22.09 Million USD | 65.315% |
| Prenetics Global Limited | 21.74 Million USD | 64.748% |
| Prenetics Global Limited | 21.74 Million USD | 64.748% |
| Precipio, Inc. | 15.19 Million USD | 49.564% |
| Personalis, Inc. | 73.48 Million USD | 89.569% |
| RadNet, Inc. | 1.61 Billion USD | 99.526% |
| Sera Prognostics, Inc. | 306 Thousand USD | -2404.831% |
| Sotera Health Company | 1.04 Billion USD | 99.27% |
| Neuronetics, Inc. | 71.34 Million USD | 89.257% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 83.259% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 83.259% |
| Trinity Biotech plc | 56.83 Million USD | 86.513% |
| T2 Biosystems, Inc. | 7.19 Million USD | -6.559% |
| Twist Bioscience Corporation | 312.97 Million USD | 97.551% |
| Exagen Inc. | 52.54 Million USD | 85.414% |